drugset / Trial / NCT01737892

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

NCT01737892

Phase 1/2 Terminated 21 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverSingle-blindTreatment

Summary

This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous epinephrine, in healthy male and female adult volunteers. The current study is designed to complement an earlier PK study, API-E004-CL-B, for a more thorough evaluation of the E004 PK. Safety of E004 will also be evaluated.

Timeline

Start
2012-11
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject E004-d3 Unknown 125 ug Inhaled
Comparator Epinephrine Other / unclassified 220 ug Inhaled

Indications